bluuebunny/crossref_metadata_2025_split huggingface dataset:
1005-P: Efficacy and Safety of Evogliptin in a Brazilian T2DM Population—A Bridging Study
Authors: FORTI ADRIANA C. , FELÍCIO JOÃO SOARES , RUSSO LUIS AUGUSTO , BORGES JOAO LINDOLFO , CHACRA ANTONIO R. , SALLES JOAO EDUARDO , CERCATO CINTIA 
Published: June 2019

Ethnicity is a known factor for DPP-4 inhibitors (DPP-4i)response in type 2 diabetes mellitus (T2DM). A bridging study was conducted to confirm the approved dosage of Evogliptin (EVO), in Korea (once daily 5mg) and the safety for the Brazilian population. In this randomized, double-blind, double-dummy, parallel trial, 146 T2DM patients (male: 50.7%; age: 51.5 ± 10.2 years; time from T2DM diagnosis: 1.7 ± 3.5 years; baseline HbA1c: 8.9 ± 0.9%) with inadequate glycemic control on diet and exercise were randomly assigned to a 12-week once daily treatment with EVO 2,5 mg, EVO 5 mg, EVO 10 mg or sitagliptin (SITA) 100 mg.T2DM patients aged 20 to 75 years, with 7.5% ≤ HbA1c ≤ 10.5% at screening, and who have not been on any hypoglycemic agent within 12 weeks prior to screening were eligible for the study. Subjects with fasting plasma glucose ≥ 300 mg/dL at screening in the presence of severe signs/symptoms of T2DM were excluded. Sample size was estimated to identify a clinically relevant HbA1c mean reduction ≥ 0,5% within each treatment group. Change from baseline to Week 12 (mean; 90% CI) in HbA1c (%) and, fasting plasma glucose levels (mg/dL) was calculated. Treatment effects on HbA1c and fasting glucose levels adjusted by baseline HbA1c, fasting plasma glucose and BMI were also estimated. The results confirmed the clinical benefit of a daily EVO 5,0 mg regimen in the Brazilian population.

Disclosure
A.C. Forti: None. J.S. Felício: None. L.A. Russo: None. J. Borges: None. A.R. Chacra: None. J.E. Salles: Board Member; Spouse/Partner; AstraZeneca, Merck & Co., Inc., Novo Nordisk A/S. Other Relationship; Spouse/Partner; Eurofarma Laboratórios S.A. C. Cercato: Board Member; Self; Novo Nordisk Inc. Research Support; Self; Eurofarma, Novo Nordisk Inc.

Funding
Eurofarma Laboratórios S.A.
1007-P: Incretin Therapy with DPP-4-I and GLP1-RA for the Hospital Management of Elderly Adults with Type 2 Diabetes
Authors: FAYFMAN MAYA , ANZOLA ISABEL , URRUTIA MARIA A. , PASQUEL FRANCISCO J. , GALINDO RODOLFO J. , CARDONA SAUMETH , WANG HEQIONG , UMPIERREZ GUILLERMO E. 
Published: June 2019

Management of hospitalized older adults (&gt; 65 years) with T2D is challenging and associated with increased risk of hypoglycemia. Incretin-based therapy with DPP-4i and GLP-1RA have been shown to be safe and efficacious in hospitalized patients with mild-moderate hyperglycemia. We performed a post hoc pooled analysis of 4 randomized controlled trials comparing DPP-4i and GLP-1RA alone or in combination with basal insulin to basal-bolus regimen in older adults in non-ICU settings. The primary endpoint was percentage of BG readings within target range (70-180 mg/dL). Secondary endpoints included mean hospital BG, hypoglycemia and a composite of hospital complications.
Among a total of 192 elderly patients, 88 (45.8%) received basal+bolus, 52 (27%) incretin+basal, and 52 (27%) incretin therapy alone. All treatment groups had improvement in glycemic control with no differences in % BG between 70-180 mg/dL or in the mean daily BG, or hospital complications between groups (Table). Patients treated with basal+bolus insulin had the highest rate of hypoglycemia. No differences were found on % of BG readings within range of 70-180 mg/dl (primary outcome) for patients with randomization BG ≤ 200 mg/dL or BG &gt; 200 mg/dl.
In summary, incretin therapy is safe and associated with similar glycemic control and lower rates of hypoglycemia compared to basal+bolus regimen among elderly hospitalized adults with T2D.

Disclosure
M. Fayfman: None. I. Anzola: None. M.A. Urrutia: None. F.J. Pasquel: Consultant; Self; Boehringer Ingelheim Pharmaceuticals, Inc., Merck & Co., Inc. R.J. Galindo: Advisory Panel; Self; Abbott, Novo Nordisk Inc., Sanofi US. Research Support; Self; Novo Nordisk Inc. S. Cardona: None. H. Wang: None. G.E. Umpierrez: Advisory Panel; Self; Boehringer Ingelheim Pharmaceuticals, Inc., Janssen Pharmaceuticals, Inc. Research Support; Self; AstraZeneca, Merck & Co., Inc., Novo Nordisk Inc., Sanofi US.
101-LB: Real-Time Monitoring of Cholesterol Levels Using a Microfluidic Device
Authors: BHUSHAN ABHINAV , KARNIK SONALI J. 
Published: June 2019

The lack of point-of-care (POC) devices that continuously monitor health is an unmet need. The challenge is not just to create POC devices, but to also go beyond the single time point or discrete measurements. For instance, in a critical in-patient setting, the need to monitor patients’ biochemical signals is important; discrete POC devices are not effective and increase clinical burden. For example, continuous glucose monitors have made it easier for patients to track glucose levels, there are currently no other similar devices either in POC or in an in-patient setting. We had previously reported results in which we carried out, in real-time, continuous measurement of albumin from hepatocytes as a marker of liver function. These measurements were carried out at high sensitivity (∼fg) and temporal resolution (&lt;20s) (10.1007/s10544-017-0244-6). In this abstract, we now report novel POC devices that utilize smart chemistry to carry out continuous, real-time measurement of cholesterol using a tiny sample volume (∼1ul) and achieving detection limit surpassing the conventional assays. The response of hepatocytes to simvastatin was accurately measured by the device, again in real-time. Since the devices are easily customizable, by simply changing the enzymes used in the reactions, we can measure glucose, lactate, and urea. These devices can be groundbreaking in personalized tracking of metabolic health in a POC setting as well as for in-patient situation to assess treatments of ongoing interventions without increasing clinical burden.

Disclosure
A. Bhushan: None. S.J. Karnik: None.

Funding
National Institutes of Health (DK095984)
1015-P: Effects of the Oral, Small Molecule GLP-1R Agonist TTP273 on Patients with Stage 2 Hypertension: Results from a Post Hoc Analysis of the Phase 2 Logra Study
Authors: VALCARCE CARMEN , DUNN IMOGENE , FREEMAN JENNIFER L.R. 
Published: June 2019

TTP273, an oral, non-peptide GLP-1R agonist showed significant placebo-subtracted reductions in A1c of 0.9 and 0.7% when dosed at 150mg QPM or BID, respectively, in LOGRA, a 12-week, phase 2, double-blind, placebo-controlled randomized study [Diabetes 2017 Jun; 66 (S 1) A326]. In addition, less nausea was observed in the active groups than in the placebo group and the only incidence of vomiting occurred in the placebo group.
A post hoc analysis of patients from the LOGRA study with Stage 2 hypertension that completed 12 weeks of dosing revealed a subgroup with a nominally statistically significant reduction in systolic blood pressure (SBP). Entry criteria allowed patients on standard of care treatment for hypertension, but excluded patients with persistent, uncontrolled hypertension at screening (SBP ≥ 160mmHg and/or diastolic blood pressure (DBP) ≥ 90mmHg). Approximately 25% of the patients that completed the study were considered to have Stage 2 hypertension at baseline (defined by SBP ≥ 140mmHg or DBP ≥90mmHg) and around 75% of those patients received 1 or more concomitant medications to treat hypertension.
Among treatment groups, characteristics were relatively well balanced with an approximately equal number of patients enrolled per treatment group with similar baseline values for SBP/DBP and pulse rate among treatment groups (mean baseline values of 147/85 mmHg and 73 bpm). The post hoc analysis demonstrated a mean decrease from baseline in SBP of 17 in the 150mg QPM arm (n=9) (p &lt; 0.05 vs. placebo), 12 in the 150mg BID TTP273 arm (n=10) and of 6 mmHg in the placebo arm (n=8), respectively. No significant changes in DBP or pulse rate were observed with either active group compared to placebo.
Results from this post hoc analysis suggest that TTP273 could provide an additional benefit of reducing SBP, in line with other GLP-1R agonists. Unlike other GLP-1R agonists, these effects occurred without the side effects of nausea and vomiting.

Disclosure
C. Valcarce: Employee; Self; vTv Therapeutics. I. Dunn: None. J.L.R. Freeman: Employee; Self; vTv Therapeutics. Stock/Shareholder; Spouse/Partner; vTv Therapeutics.
1018-P: Comparison of Short- and Long-Acting Glucagon-Like Peptide-1 Receptor Agonist Effects on Postprandial Glucose and Lipid Excursion via Gastric Emptying
Authors: KUWATA HITOSHI , YABE DAISUKE , HAMAMOTO YOSHIYUKI , KUROSE TAKESHI , SEINO YUTAKA 
Published: June 2019

Background: It has been suggested that short- and long-acting glucagon-like peptide 1 receptor agonists (GLP-1RAs) exert different actions on gastric emptying rate (GE). However, the alterations in gastric emptying and their contributions to postprandial glucose and lipid excursions have not been fully evaluated.
Methods: A 3-arm non-randomized trial was conducted in Japanese patients with type 2 diabetes. Meal tolerance test was performed before and 12 weeks after initiation of treatment by short-acting GLP-1RA (Lixisenatide (X)) or long-acting GLP-1RA [Liraglutide (R) or Dulaglutide(D)]. Plasma glucose, ApoB48, insulin and gastric emptying (13C breath test) were measured after taking a solid test meal. Data were presented as average±SD and evaluated using student’s or paired t-test. p&lt;0.05 was considered significant.
Results: 18 patients were enrolled [X: n=7; age(year) 45.6±2.3; duration(year) 4.6±5.0; ΔCPR(glucagon stimulation test (mg/dl) 3.2±1.4, R: n=6; age 49.0±11.4; duration 8.2±9.2; ΔCPR 3.1±0.5, D; n=5; age 51.8±7.6; duration 4.6±3.8; ΔCPR 2.7±1.3)]. After 12 weeks administration, HbA1c was significantly improved in all groups [HbA1c (%), X: 8.2±1.6 to 6.3±0.4, L: 9.0±0.8 to 6.6±1.1, D: 8.6±0.9 to 6.6±0.3]. GE was delayed only in X [T1/2(min), X: 26.4±6.5 to 64.4±34.4, L: 33.5±15.5 to 29.1±9.2, and D: 26.3±3.8 to 31.1±9.7]. Postprandial insulin and ApoB48 secretion was significantly decreased only in X [IRI-AUC0-240(uIU/dlxmin), X: 11724.0±5582.0 to 6248.2±3718.7, L: 8206.7±3075.4 to 9905.0±3450.3, D: 9832.8±5087.3 to 10640.6±4195.1 and ApoB48-iAUC0-240(ug/mlxmin), X: 513.2±394.4 to -83.7±242.6; L: 745.1±352.4 to 534.1±193.4; and D: 983.5±239.0 to 568.2±374.4].
Conclusion: These results indicate that short-acting agents improve postprandial glycemic and lipidemic metabolism through delaying GE; long-acting agents improve glycemic control through enhanced insulin secretion.

Disclosure
H. Kuwata: Research Support; Self; Eli Lilly and Company. D. Yabe: Advisory Panel; Self; Abbott. Research Support; Self; Astellas Pharma Inc. Speaker's Bureau; Self; AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., Daiichi Sankyo Company, Limited, Eli Lilly and Company, Merck Sharp & Dohme Corp., Novo Nordisk Inc., Ono Pharmaceutical Co., Ltd., Sanofi K.K., Taisho Pharmaceutical Co., Ltd., Takeda Pharmaceutical Company Limited. Y. Hamamoto: Speaker's Bureau; Self; Novo Nordisk A/S. T. Kurose: Consultant; Self; Taisho Pharmaceutical Co., Ltd. Speaker's Bureau; Self; FujiFilm Pharma, Ono Pharmaceutical Co., Ltd. Y. Seino: Research Support; Self; Arkray, Inc., Boehringer Ingelheim Pharmaceuticals, Inc., Eli Lilly and Company, Merck & Co., Inc., Novo Nordisk Inc., Ono Pharmaceutical Co., Ltd., Taisho Pharmaceutical Co., Ltd., Takeda Pharmaceutical Company Limited, Terumo Medical Corporation.
1024-P: Effect of Tirzepatide, a Dual GIP and GLP-1 Receptor Agonist, on Glycemic Control and Body Weight in Japanese Patients with T2DM
Authors: OHWAKI KENJI , FURIHATA KENICHI , MIMURA HANAKA , OURA TOMONORI , IMAOKA TAKESHI 
Published: June 2019

Tirzepatide (TZP), a novel dual GIP and GLP-1 receptor agonist (RA), has shown superior glycemic control and weight loss compared to a selective GLP-1 RA. A Phase 1, double-blind, placebo-controlled, randomized, parallel-dose group, 8-week multiple ascending dose study investigated safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of TZP administered QW in 48 Japanese patients with T2DM. This study consisted of 1 fixed dose (5 mg) and 2 dose titration (2.5-2.5-5-5-10-10-10-10 mg and 5 5 10 10 10 10 15 15 mg) cohorts of TZP. With TZP, there were marked reductions from baseline to Week 8 in fasting serum glucose, HbA1c, and body weight. The half-life of plasma TZP concentration was approximately 5 days and supports QW dosing regimen. All doses of TZP were well tolerated. The most frequently reported treatment-emergent adverse events (AEs) were decreased appetite and gastrointestinal AEs (constipation, diarrhea, abdominal discomfort, abdominal distension, vomiting, and nausea). These AEs were generally dose dependent and mild in severity. The safety, tolerability, PK, and PD profiles of TZP in this study appeared comparable to other Phase 1 and 2 studies in non-Japanese patients with T2DM. The data support Phase 3 development of TZP for QW dosing in Japanese patients with T2DM.

Disclosure
K. Ohwaki: Employee; Self; Eli Lilly and Company. K. Furihata: None. H. Mimura: Employee; Self; Eli Lilly and Company. T. Oura: Employee; Self; Eli Lilly and Company. Stock/Shareholder; Self; Eli Lilly and Company. T. Imaoka: Employee; Self; Eli Lilly and Company.
1038-P: Results of Interim Analysis of a Randomized Crossover Study in Type 1 Diabetes (T1D) of a Dual-Hormone Closed-Loop System with Xerisol™ Glucagon vs. Insulin-Only Closed-Loop System vs. a Predictive Low Glucose Suspend System
Authors: WILSON LEAH M. , JACOBS PETER G. , RESALAT NAVID , REDDY RAVI , YOUSSEF JOSEPH EL , BRANIGAN DEBORAH , LEITSCHUH JOSEPH A. , SENF BRIAN , GABO VIRGINIA , CASTLE JESSICA R. 
Published: June 2019

Dual-hormone systems show promise to reduce hypoglycemia, but require a stable liquid glucagon formulation. XeriSol™ glucagon is a shelf-stable glucagon product for this use. Nineteen subjects with T1D are completing a single-center three-day outpatient study comparing control modes of the Oregon Artificial Pancreas system: 1) dual hormone (DH) closed-loop with Novolog™ insulin and XeriSol™ glucagon, 2) insulin-only single hormone (SH) closed-loop, 3) insulin-only predictive low glucose suspend system (PLGS). In clinic aerobic exercise (45 minutes at 60% VO2max) and home exercise was completed with each arm. SH and DH used automated exercise detection to adaptively dose insulin/glucagon for predicted hypoglycemia and tailored mealtime dosing based on past meal responses with an adaptive algorithm. An interim analysis after 7 subjects was completed for safety. The primary outcome measures are % time 70-180 mg/dL and % time &lt;70 mg/dL for the 3-day study and the 4-hour period from start of exercise until the next meal. From start of exercise until the next meal, DH showed a clinically meaningful reduction of time in hypoglycemia compared with PLGS and SH. For the entire study, DH showed a clinically meaningful lower time &lt;70mg/dL. No serious events or unexpected side effects occurred.

Disclosure
L.M. Wilson: None. P.G. Jacobs: Stock/Shareholder; Self; Pacific Diabetes Technologies. N. Resalat: None. R. Reddy: None. J. El Youssef: None. D. Branigan: None. J.A. Leitschuh: Other Relationship; Self; AgaMatrix. B. Senf: None. V. Gabo: None. J.R. Castle: Advisory Panel; Self; Novo Nordisk Inc., Zealand Pharma A/S. Consultant; Self; Dexcom, Inc. Research Support; Self; Dexcom, Inc., Xeris Pharmaceuticals, Inc.

Funding
JDRF
1044-P: Insulin Intensification with a 24-Hour Wearable Insulin Delivery Device in Patients Inadequately Controlled with Basal Insulin Therapy
Authors: ZEIDAN TRISHA , NIKKEL CARLA C. , DZIENGELEWSKI ELIZABETH A. 
Published: June 2019

A stepwise approach for the addition of prandial insulin is recommended when intensification from basal to basal-bolus therapy is required. Rationale for this approach includes patient resistance to multiple daily injections and a stepwise approach has been associated with lower rates of hypoglycemia. Unfortunately, evidence suggests within a year of initiating prandial insulin, up to 75% of patients require full basal-bolus therapy. This results in the ongoing need to address the same barriers that initially delayed intensification to full basal-bolus therapy. In light of these considerations, insulin delivery options that simplify basal-bolus therapy while offering clinical benefit without increased safety risk may be an attractive option. This study retrospectively evaluated the use of a wearable basal-bolus insulin delivery device (V-Go) in 73 patients with type 2 diabetes inadequately controlled with basal insulin. Change in A1C, insulin basal and total daily doses (TDD) and prevalence of hypoglycemia were analyzed. Mean ± SD characteristics at baseline included duration of diabetes 12 ± 7 years, A1C 9.6 ± 1.5%, basal TDD 52 ± 34 u/day (range 10 to 170), and basal TDD 0.53 ± 0.35 u/kg. Concomitant anti-hyperglycemic agents were prescribed in 93% of patients. After a mean of 5 months of V-Go use, mean ± SD reductions in A1C (-1.3 ± 1.5%; p&lt;0.0001) and basal TDD (-22 ± 30 u/day; p&lt;0.0001 and -0.24 ± 0.31 u/kg; p&lt;0.0001) were observed. Compared to baseline, TDD was similar on V-Go, 52 ± 18 u/day; p=0.946, however, insulin dose was redistributed to incorporate prandial coverage (22 ± 9 u/day) and basal coverage (30 ± 13 u/day). With V-Go use, severe hypoglycemia was reduced from 10% at baseline to 3% and fewer concomitant agents were prescribed. Intensification from basal insulin to basal-bolus therapy with V-Go was effective and resulted in a lower prevalence of hypoglycemia.

Disclosure
T. Zeidan: Advisory Panel; Self; Corcept Therapeutics. Research Support; Self; Valeritas, Inc. Speaker's Bureau; Self; AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., Lilly Diabetes, Valeritas, Inc. C.C. Nikkel: Employee; Self; Valeritas, Inc. Stock/Shareholder; Self; Valeritas, Inc. E.A. Dziengelewski: Employee; Self; Valeritas, Inc. Stock/Shareholder; Self; Valeritas, Inc.
1046-P: Day-to-Day Variability of Insulin Requirements in Inpatients on General Wards
Authors: BOUGHTON CHARLOTTE K. , BALLY LIA , THABIT HOOD , HARTNELL SARA , HERZIG DAVID , VOGT ANDREAS , ANDEREGGEN EVELINE , RUAN YUE , WILINSKA MALGORZATA E. , EVANS MARK , WERTLI MARIA M. , COLL ANTHONY P. , STETTLER CHRISTOPH , HOVORKA ROMAN 
Published: June 2019

Aim: To characterize variability of exogenous insulin requirements during fully closed-loop insulin delivery in hospitalized patients with hyperglycaemia requiring subcutaneous insulin.
Methods: We retrospectively analyzed data from randomized trials investigating fully closed-loop insulin delivery for up to 15 days in inpatients with hyperglycaemia on general wards (type 1 diabetes excluded). We calculated insulin amounts delivered by closed-loop overnight (2300-0449), during breakfast (0500-1059), lunch (1100-1659), and evening meal (1700-2249). The coefficient of variation (CV) quantified between day and between night variability of insulin requirements in inpatients using closed-loop for at least 5 days.
Results: Data from 487 days in 55 participants were analyzed [age 69(8)years, weight 100(32)kg, baseline HbA1c 8.0(2.1)%, duration of diabetes 18(13)years, duration of insulin 9(10)years, mean(SD)]; 14.5% of participants received dialysis, 29.1% enteral/parenteral nutrition and 21.8% steroids. Closed-loop directed insulin infusion rate was 1.6(0.8), 2.9(1.2), 3.1(1.4), 2.1(1.0)units/kg/h during overnight, breakfast, lunch, and evening meal periods, respectively. The CV of insulin delivery was higher between nights than between any of the daytime periods [overnight 54(21)% compared with 42(21)% at breakfast, 41(16)% lunchtime and 48(17)% dinner; p=0.001].
Conclusions: Overnight exogenous insulin requirements are more variable than daytime requirements. Particular attention needs to be paid to glucose management overnight to prevent dysglycaemia in inpatients receiving insulin therapy on general wards.

Disclosure
C.K. Boughton: None. L. Bally: None. H. Thabit: Research Support; Self; Dexcom, Inc. S. Hartnell: Advisory Panel; Self; Dexcom, Inc., JDRF. Speaker's Bureau; Self; Sanofi. D. Herzig: None. A. Vogt: None. E. Andereggen: None. Y. Ruan: None. M.E. Wilinska: None. M. Evans: Advisory Panel; Self; Dexcom, Inc., Medtronic, Roche Diabetes Care, Zucara Therapeutics Inc. Research Support; Self; MedImmune, Sanofi. Speaker's Bureau; Self; AstraZeneca. Other Relationship; Self; Abbott, Eli Lilly and Company, Novo Nordisk Inc. M.M. Wertli: None. A.P. Coll: None. C. Stettler: None. R. Hovorka: Advisory Panel; Self; Novo Nordisk A/S. Research Support; Self; Abbott, Dexcom, Inc., Medtronic. Speaker's Bureau; Self; Eli Lilly and Company, Novo Nordisk A/S. Other Relationship; Self; B. Braun Medical Inc., Medtronic.
1048-P: Insulin Pump Catheters Can Be Worn Much More Than the Recommended Three Days
Authors: ARDILOUZE JEAN-LUC , GOBEIL FERNAND , MENARD JULIE , BOVAN DANIJELA , MESSIER VIRGINIE , SAVARD MARTIN , BAILLARGEON JEAN-PATRICE , RABASA-LHORET RÉMI 
Published: June 2019

Background and Objectives: Current recommendation is to change insulin pump catheters every 3 days. The rational supporting this recommendation is weak, mostly historical or anecdotical, and based on habits. Our objective was to determine catheter length of wearing under day-to-day condition.
Methods: Participants with type 1 diabetes (T1D) worn their usual catheter during 2 periods as long as glycemic control was acceptable and insertion site remained comfortable. Data are presented as means ± standard deviations. Hypoglycemia (≤ 3.5 mmol/L) and hyperglycemia (≥ 13.8 mmol/L) were recorded via self-monitoring of blood glucose or continuous glucose monitoring. Each experimental period was separated by a 1-week washout, consisting of the usual catheter management.
Results: Participants (n=22, 12 males, age: 47.1±16.2 years, BMI: 26.6±4.1 kg/m2, duration of T1D: 27.5±14.3 years, pump therapy: 8.8±6.2 years, 14 using Medtronic, 8 using Animas, usual catheter wearing: 3.5±0.5 days, insulin: 51.7±15.5 units/day, A1c: 7.4±0.8%) completed 41/44 periods (348.7 experimental days; one subject quitted, 2 catheters accidentally ripped-out). Catheters were worn 8.18±2.93 days, the shortest and the longest periods were respectively 3.81 and 15.61 days. Reasons for removal were uncontrolled glycemia despite bolusing (73%), discomfort (15%), or both (12%). Number of hypoglycemia and hyperglycemia per day were 0.18±0.17 and 0.90±0.56, respectively. No severe hypoglycemia, nor hyperglycemia ≥ 20 mmol/L or ketosis were observed over the study.
Conclusions: Catheters might be worn beyond 3 days, up to 8 days and possibly more, significantly reducing patients and financial burden. Longer-term data are required to ensure that longer catheter wearing is not associated with impact on glucose control or lipohypertrophy.

Disclosure
J. Ardilouze: None. F. Gobeil: None. J. Menard: None. D. Bovan: None. V. Messier: Other Relationship; Self; Eli Lilly and Company. M. Savard: None. J. Baillargeon: None. R. Rabasa-Lhoret: Advisory Panel; Self; AstraZeneca, Boehringer Ingelheim International GmbH, Janssen Pharmaceuticals, Inc., Lilly Diabetes, Merck & Co., Inc., Novo Nordisk A/S, Sanofi. Research Support; Self; AstraZeneca, Janssen Pharmaceuticals, Inc., Novo Nordisk A/S.

Funding
JDRF